Artia Global Partners LP Makes New $1.15 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Artia Global Partners LP bought a new position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 20,811 shares of the company's stock, valued at approximately $1,152,000. Artia Global Partners LP owned approximately 0.05% of Tarsus Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TARS. Barclays PLC lifted its stake in Tarsus Pharmaceuticals by 345.9% in the 3rd quarter. Barclays PLC now owns 98,663 shares of the company's stock worth $3,246,000 after purchasing an additional 76,538 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Tarsus Pharmaceuticals by 9.3% in the third quarter. Franklin Resources Inc. now owns 12,164 shares of the company's stock worth $444,000 after buying an additional 1,033 shares in the last quarter. Exome Asset Management LLC purchased a new position in Tarsus Pharmaceuticals during the 3rd quarter valued at approximately $1,500,000. Lord Abbett & CO. LLC increased its stake in Tarsus Pharmaceuticals by 28.4% in the 3rd quarter. Lord Abbett & CO. LLC now owns 594,876 shares of the company's stock worth $19,565,000 after acquiring an additional 131,636 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its stake in Tarsus Pharmaceuticals by 2,088.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company's stock worth $14,477,000 after acquiring an additional 420,057 shares during the last quarter. Institutional investors own 90.01% of the company's stock.

Analyst Ratings Changes

TARS has been the topic of several research reports. HC Wainwright restated a "buy" rating and issued a $73.00 price target on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Jefferies Financial Group boosted their target price on shares of Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. Oppenheimer boosted their price objective on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an "outperform" rating in a research note on Wednesday, January 22nd. Barclays lowered their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th. Finally, Guggenheim restated a "buy" rating and set a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday, February 24th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $63.67.

Tarsus Pharmaceuticals Trading Down 3.1 %

Tarsus Pharmaceuticals stock traded down $1.61 during trading hours on Thursday, hitting $50.30. The company had a trading volume of 1,057,321 shares, compared to its average volume of 695,017. The firm has a market cap of $1.93 billion, a P/E ratio of -13.20 and a beta of 0.94. The company has a 50-day moving average price of $47.73 and a two-hundred day moving average price of $48.57. Tarsus Pharmaceuticals, Inc. has a 1 year low of $20.08 and a 1 year high of $57.28. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.64) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.05. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. On average, sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current year.

Insider Activity

In related news, insider Dianne C. Whitfield sold 2,315 shares of the business's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $107,161.35. Following the completion of the transaction, the insider now owns 50,751 shares of the company's stock, valued at $2,349,263.79. The trade was a 4.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, General Counsel Bryan Wahl sold 3,341 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $46.29, for a total value of $154,654.89. Following the sale, the general counsel now directly owns 58,057 shares in the company, valued at $2,687,458.53. This trade represents a 5.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,542 shares of company stock worth $1,581,173. Company insiders own 8.25% of the company's stock.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.